News
Home>News & Events>Presentations>CPP>The Coalition Against Major Diseases: Dopamine Transmitter Neuroimaging as an Enrichment Biomarker to Enable Parkinson’s Disease Clinical Trials
109
Related Posts
-
Dr. Stephenson’s presentation at University of Texas Health, San Antonio, The Perry and Ruby Stevens Parkinson’s Disease Center of Excellence: “Critical Path for Parkinson’s Collaboration to Enable Patient Focused Drug Development and Precision Medicine”
-
Using Data to Reimagine Clinical Trials
-
The FDA is Listening: Integrating the Voice of the Patient in Drug Development for Parkinson’s and Huntington’s Diseases
-
The Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression Through Quantitative Medicine
-
Global Regulatory Agencies Support the Use of Dopamine Transporter Neuroimaging for Subject Selection in Clinical Trials Targeting Early Stage Parkinson’s Disease